Health disparities in breast cancer: Biology meets socioeconomic status

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 281-292

  Dunn, Barbara K ^a   Agurs Collins, Tanya ^a   Browne, Doris ^b   Lubet, Ronald ^a   Johnson, Karen A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Browne and Associates Inc   (United States)

Author keywords

Breast cancer; Epidemiology; Estrogen receptor negative; Health disparities; Risk factors; Targeted therapy

Indexed keywords

BEVACIZUMAB; BEXAROTENE; BSI 201; CALCIUM; CETUXIMAB; CYTOKERATIN 5; CYTOKERATIN 6; DASATINIB; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FOLIC ACID; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHYTOESTROGEN; PLATINUM COMPLEX; PROGESTERONE RECEPTOR; SUNITINIB; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CALCIUM INTAKE; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CAUCASIAN; CLINICAL TRIAL; DIETARY FIBER; DRUG TARGETING; HEALTH DISPARITY; HISTOPATHOLOGY; HUMAN; LIFESTYLE; NEGRO; NONHUMAN; NUTRITIONAL HEALTH; OVARIECTOMY; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; SOCIAL STATUS;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HUMANS; RECEPTORS, ESTROGEN; SOCIOECONOMIC FACTORS;

EID: 77953028390     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0827-x     Document Type: Review

References (109)

1. Browne D (2008) Public Health Democracy: U.S. and Global Health Disparities in Breast Cancer. Woodrow Wilson International Center for Scholars, Global Health Initiative, Washington, DC www.wilsoncenter.org/globalhealth
2. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100: 1804-1814. doi: 10.1093/jnci/djn411.
3. Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100: 1643-1648. doi: 10.1093/jnci/djn344
4. Morris GJ, Mitchell EP (2008) Higher incidence of aggressive breast cancers in African-American women: a review. J Natl. Med Assoc 100: 698-702
5. McBride R, Hershman D, Tsai WY, Jacobson JS, Grann V, Neugut AI (2007) Within-stage racial differences in tumor size and number of positive lymph nodes in women with breast cancer. Cancer 110: 1201-1208. doi:10.1002/cncr.22884 (Pubitemid 47435589)
6. ACS (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta, GA. [http://www.cancer.org/downloads/STT/ cffaa-2009-2010.pdf]
7. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC (2009) Trends in area-socioeconomic and raceethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev 18: 121-131. doi: 10.1158/1055-9965.EPI-08-0679
8. Haas JS, Earle CC, Orav JE, Brawarsky P, Keohane M, Neville BA, Williams DR (2008) Racial segregation and disparities in breast cancer care and mortality. Cancer 113: 2166-2172. doi: 10.1002/cncr.23828
9. Hershman DL, Unger JM, Barlow WE, Hutchins LF et al (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest oncology studies S8814/S8897. J Clin Oncol 27: 2157-2162. doi: 10.1200/JCO.2008.19.1163
10. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM (1991) C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68: 331-334
11. Porter PL, Lund MJ, Lin MG, Yuan X et al (2004) Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100: 2533-2542. doi:10.1002/cncr. 20279
12. Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 66: 8327-8330. doi: 10.1158/0008-5472.CAN-06-1927 (Pubitemid 44449138)
13. Carey LA, Perou CM, Livasy CA, Dressier LG et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502. doi: 10.1001/jama.295. 21.2492 (Pubitemid 43854964)
14. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ et al (2007) Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 14: 2994-3003. doi: 10.1245/s10434-007-9477-6
15. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH et al (2008) Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American, women. Am J Surg 195: 153-158. doi: 10.1016/j.amjsurg.2007.09. 033
16. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ et al (2004) Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 10: 2052-2057 (Pubitemid 38375566)
17. Nalwoga H, Ames JB, Wabinga H, Akslen LA (2007) Frequency of the basal-like phenotype in African breast cancer. APMIS 115: 1391-1399. doi: 10.1111/j.1600-0463.2007.00862.X
18. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL (2008) Early onset of breast cancer in a group of British black women. Br J Cancer 98: 277-281. doi:10.1038/sj.bjc.6604174 (Pubitemid 351161260)
19. Hennis AJ, Hambleton IR, Wu SY, Leske MC, Nemesure B (2009) Breast cancer incidence and mortality in a Caribbean population: comparisons with African-Americans. Int J Cancer 124: 429-433. doi: 10.1002/ijc.23889
20. Schneider BP, Winer EP, Foulkes WD, Garber J et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14: 8010-8018. doi:10.1158/1078-0432.CCR-08-1208
21. Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52: 108-118. doi:10.1111/j.1365-2559.2007.02889.x
22. Nagle RB, Bocker W, Davis JR, Heid HW, Kaufmann M, Lucas DO, Jarasch ED (1986) Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 34: 869-881 (Pubitemid 16067456)
23. Dairkee S, Heid HW (1993) Cytokeratin profile of immunomagnetically separated epithelial subsets of the human mammary gland. In Vitro Cell Dev Biol Anim 29A: 427-432 (Pubitemid 23187765)
24. Gusterson BA, Ross DT, Heath VJ, Stein T (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7: 143-148. doi:10.1186/bcr1041
25. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49: 22-34. doi: 10.1111/ J.1365-2559.2006.02453.X (Pubitemid 43972917)
26. Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31: 205-262
27. van de Rijn M, Perou CM, Tibshirani R, Haas P et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996 (Pubitemid 35434844)
28. Nielsen TO, Hsu FD, Jensen K, Cheang M et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374. doi: 10.1158/1078-0432.CCR-04-0220
29. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26: 2568-2581. doi: 10.1200/JCO.2007.13.1748
30. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19: 264-271. doi: 10.1038/modpathol.3800528 (Pubitemid 43117611)
31. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8: 235-244. doi: 10.1016/S1470-2045(07)70074-8 (Pubitemid 46291713)
32. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800. doi:10.1056/NEJM ra.0801289
33. Prat A, Perou CM (2009) Mammary development meets cancer genomics. Nat Med 15: 842-844. doi:10.1038/nm0809-842
34. Lim E, Vaillant F, Wu D, Forrest NC et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913. doi: 10.1038/nm.2000
35. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95: 1482-1485 (Pubitemid 37279334)
36. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen, receptor and basal phenotype. Clin Cancer Res 11: 5175-5180. doi: 10.1158/1078-0432.CCR-04-2424
37. Atchley DP, Albarracin CT, Lopez A, Valero V et al (2008) Clinical and pathologic characteristics of patients with BRCApositive and BRCA-negative breast cancer, J Clin Oncol 26: 4282-4288. doi: 10.1200/JCO.2008.16.6231
38. Perou CM, Sorlie T, Eisen MB, van de Rijn M et al (2000) Molecular portraits of human breast tumours. Nature 406: 747-752. doi: 10.1038/35021093
39. Sorlie T, Perou CM, Tibshirani R, Aas T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874. doi: 10.1073/pnas. 191367098 (Pubitemid 32878711)
40. Foekens JA, Atkins D, Zhang Y, Sweep FC et al (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24: 1665-1671. doi:10.1200/JCO.2005.03.9115
41. Tavtigian SV, Pierotti MA, Borresen-Dale AL (2006) International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'. Breast Cancer Res 8: 303. doi:10.1186/bcr1609
42. Parker JS, Mullins M, Cheang MC, Leung S et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167. doi:10.1200/JCO.2008. 18.1370
43. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F (2007) Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 18: 1285-1286. doi: 10.1093/annonc/mdm360
44. Cheang MC, Voduc D, Bajdik C, Leung S et al (2008) Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376. doi:10.1158/1078-0432. CCR-07-1658 (Pubitemid 351413917)
45. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 112: 737-747, doi:10.1002/cncr. 23243
46. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13: 477-493. doi: 10.1634/theoncologist.2007-0248 (Pubitemid 351872866)
47. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H (2009) Clinical significance of basal-like subtype in triplenegative breast cancer. Breast Cancer 16: 260-267. doi: 10.1007/s12282-009-0150-8
48. Chlebowski RT, Chen Z, Anderson GL, Rohan T et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl. Cancer Inst 97: 439-448. doi: 10.1093/jnci/dji064 (Pubitemid 40528607)
49. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M et al (2007) Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9: R16. doi:10.1186/bcr1649
50. Millikan RC, Newman B, Tse CK, Moorman PG et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123-139. doi :10.1007/s10549-007-9632-6
51. Ursin G, Bernstein L, Lord SJ, Karim R et al (2005) Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 93: 364-371. doi: 10.1038/sj.bjc.6602712 (Pubitemid 43080039)
52. Yang XR, Sherman ME, Rimm. DL, Lissowska J et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16: 439-443. doi:10.1158/1055-9965.EPI-06-0806 (Pubitemid 46548646)
53. Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8: R43. doi:10.1186/bcr1525
54. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113: 1521-1526. doi: 10.1002/cncr.23786
55. Clegg LX, Reichman ME, Miller BA, Hankey BF et al (2009) Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study, Cancer Causes Control 20: 417-435. doi: 10.1007/s10552-008-9256-0
56. Gordon NH (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142: 796-803
57. Taylor A, Cheng KK (2003) Social deprivation and breast cancer. J Public Health Med 25: 228-233
58. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109: 1721-1728. doi:10.1002/cncr.22618
59. Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 15: 593-602. doi: 10.1111/j. 1524-4741.2009.00822.x
60. Fung TT, Hu FB, Holmes MD, Rosner BA, Hunter DJ, Colditz GA, Willett WC (2005) Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer 116: 116-121. doi: 10.1002/ijc.20999 (Pubitemid 40827764)
61. Fung TT, Hu FB, McCullough ML, Newby PK, Willett WC, Holmes MD (2006) Diet quality is associated with the risk of estrogen receptor-negative breast cancer in postmenopausal women. J Nutr 136: 466-472 (Pubitemid 43228303)
62. Agurs-Collins T, Rosenberg L, Makambi K, Palmer JR, AdamsCampbell L (2009) Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study. Am J Clin Nutr 90: 621-628. doi:10.3945/ajcn.2009. 27666
63. Touillaud MS, Pillow PC, Jakovljevic J, Bondy ML, Singletary SE, Li D, Chang S (2005) Effect of dietary intake of phytoestrogens on estrogen receptor status in premenopausal women with breast cancer. Nutr Cancer 51: 162-169. doi:10.1207/s1532 7914nc5102-6 (Pubitemid 40734716)
64. McCann SE, Kulkarni S, Trevisan M, Vito D et al. (2006) Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status. Breast Cancer Res Treat 99: 309-311. doi : 10.1007/s10549-006-9196-x (Pubitemid 44337923)
65. Zhang M, Yang H, Holman CD (2009) Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status. Breast Cancer Res Treat 118: 553-563
66. Zhang SM, Hankinson SE, Hunter DJ, Giovannucci EL, Colditz GA, Willett WC (2005) Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev 14: 2004-2008. doi: 10.1158/1055-9965.EPI-05-0083 (Pubitemid 41161215)
67. Maruti SS, Ulrich CM, White E (2009) Folate and one-carbon metabolism nutrients from supplements and diet in relation to breast cancer risk. Am J Clin Nutr 89: 624-633. doi: 10.3945/ ajcn.2008.26568
68. Giles GG, Simpson JA, English DR, Hodge AM, Gertig DM, Macinnis RJ, Hopper JL (2006) Dietary carbohydrate, fibre, glycaemic index, glycaemic load and the risk of postmenopausal breast cancer. Int J Cancer 118: 1843-1847. doi: 10.1002/ ijc.21548
69. Park Y, Brinton LA, Subar AF, Hollenbeck A, Schatzkin A (2009) Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health-AARP Diet and Health Study. Am J Clin Nutr 90: 664-671. doi: 10.3945/ajcn.2009.27758
70. Larsson SC, Bergkvist L, Wolk A (2009) Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women. Am J Clin Nutr 89: 277-282. doi:10.3945/ajcn. 2008.26704
71. Sellers TA, Vierkant RA, Cerhan JR, Gapstur SM et al (2002) Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Cancer Epidemiol Biomarkers Prev 11: 1104-1107 (Pubitemid 35192665)
72. Robien K, Cutler GJ, Lazovich D (2007) Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study, Cancer Causes Control 18: 775-782. doi: 10.1007/s10552-007-9020-x (Pubitemid 46988245)
73. Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA (2008) Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol 168: 915-924. doi:10.1093/aje/kwn198
74. Rainville C, Khan Y, Tisman G (2009) Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series, Cases J 2: 8390. doi: 10.4076/1757-1626-2-8390
75. Dallai CM, Sullivan-Halley J, Ross RK, Wang Y et al (2007) Long-term, recreational physical activity and risk of invasive and in situ breast cancer: the California teachers study. Arch Intern Med 167: 408-415. doi:10.1001/archmte.167.4.408 (Pubitemid 46333943)
76. Peters TM, Schatzkin A, Gierach GL, Moore SC et al (2009) Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 18: 289-296. doi: 10.1158/1055-9965.EPI- 08-0768
77. Adams SA, Matthews CE, Hebert JR, Moore CG et al (2006) Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 15: 1170-1178. doi: 10.1158/1055-9965. EPI-050993
78. Bardia A, Hartmann LC, Vachon CM, Vierkant RA et al (2006) Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med 166: 2478-2483. doi: 10.1001/archinte.166.22. 2478 (Pubitemid 44913232)
79. Berclaz G, Li S, Price KN, Coates AS et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15: 875-884
80. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97: 245-254. doi: 10.1007/s1.0549-005-9118-3 (Pubitemid 43948218)
81. Olsen A, Tjonneland A, Thomsen BL, Loft S et al (2003) Fruits and vegetables intake differentially affects estrogen receptor negative and positive breast cancer incidence rates. J Nutr 133: 2342-2347 (Pubitemid 36841563)
82. Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L (2000) Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 9: 681-687 (Pubitemid 30482699)
83. Lu C, Speers C, Zhang Y, Xu X et al (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95: 1825-1833 (Pubitemid 38054683)
84. Wu K, Zhang Y, Xu XC, Hill J et al (2002) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62: 6376-6380 (Pubitemid 35364089)
85. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I et al (2007) Identification of conserved gene expression features between, murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76. doi:10.1186/gb-2007-8-5-r76
86. Bachelier R, Xu X, Li C, Qiao W, Furth PA, Lubet RA, Deng CX (2005) Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep 14: 1117-1120
87. Jones LP, Li M, Halama ED, Ma Y et al (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of Brea 1-mutation-related breast cancer. Oncogene 24: 3554-3562. doi:10.1038/sj.onc.1208426 (Pubitemid 40756225)
88. Farmer H, McCabe N, Lord CJ, Tutt AN et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921. doi:10.1038/nature03445 (Pubitemid 40559006)
89. Herschkowitz JI, He X, Fan C, Perou CM (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10: R75. doi:10.1186/bcr2142
90. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R (2001) 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice, Cancer Res 61: 7449-7455 (Pubitemid 32995033)
91. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG et al (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11: 467-474
92. Carey LA, Dees EC, Sawyer L, Gatti L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334. doi:10.1158/ 1078-0432.CCR-06-1109
93. Fong PC, Boss DS, Yap TA, Tutt A et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134. doi:10.1056/NEJMoa 0900212
94. Natrajan R, Weigelt B, Mackay A, Geyer FC et al (2009) An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat, doi: 10.1007/s10549-009-0501-3
95. Kagawa-Singer M, Dadia AV, Yu MC, Surbone A (2010) Cancer, culture, and health disparities: time to chart a new course? CA Cancer J Clin 60: 12-39. doi:10.3322/caac.20051.
96. Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer 97: 236-245. doi:10.1002/cncr.11019
97. Nanda R, Schumm LP, Cummings S, Fackenthal JD et al (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294: 1925-1933. doi:10.1001/jama.294.15.1925
98. Caulfield T, Fullerton SM, Ali-Khan SE, Arbour L et al (2009) Race and ancestry in biomedical research: exploring the challenges. Genome Med 1: 8. doi: 10.1186/gm8
99. Giri VN, Egleston B, Ruth K, Uzzo RG et al (2009) Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila Pa) 2: 244-250. doi:10.1158/1940-6207.CAPR-08-0150
100. Ross SA (2003) Diet and DNA methylation interactions in cancer prevention. Ann NY Acad Sci 983: 197-207
101. Ross SA, Dwyer J, Umar A, Kagan J, Verma M, Van Bemmel DM, Dunn BK (2008) Introduction: diet, epigenetic events and cancer prevention. Nutr Rev 66(Suppl 1): S1-S6. doi: 10.1111/ J.1753-4887.2008.00055.x
102. Levin BE (2008) Epigenetic influences on food intake and physical activity level: review of animal studies. Obesity (Silver Spring) 16(Suppl 3): S51-S54. doi:10.1038/oby.2008.518
103. Lee MP, Dunn BK (2008) Influence of genetic inheritance on global epigenetic states and cancer risk prediction with DNA methylation signature: challenges in technology and data analysis. Nutr Rev 66(Suppl 1): S69-S72. doi: 10.1111/j.1753-4887. 2008.00072.x
104. AHRQ (2008) 2007 National Healthcare Disparities Reports 2007. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality. Report No.: AHRQ Pub. No. 08-0041
105. Anonymous (2009) The right target: how survival is affected by race/ethnicity, socioeconomic status. HemOnc Today 10: 1
106. Goss E, Lopez AM, Brown CL, Wollins DS, Brawley OW, Raghavan D (2009) American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol 27: 2881-2885. doi: 10.1200/JCO.2008.21.1680
107. IOM (2003) Unequal treatment: confronting racial and ethnic disparities in healthcare. In: Smedley BD, Stith AY, Nelson AR (eds) Institute of Medicine, Washington, DC
108. Dawood S, Broglio K, Kau SW, Green MC et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27: 220-226. doi:10.1200/JCO.2008.17.9952
109. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101: 984-992. doi: 10.1093/jnci/djp175